Merck MRK, known as MSD outside the United States and Canada, and GE
Healthcare today announced a clinical study collaboration, license and supply
agreement for use of [^18F]Flutemetamol, an investigational positron emission
tomography (PET) imaging agent, to support Merck's development of MK-8931, a
novel oral beta amyloid precursor protein site cleaving enzyme (BACE)
inhibitor and Merck's lead investigational candidate for Alzheimer's disease
(AD).
Accumulation of beta amyloid in the brain is a pathological characteristic
related to Alzheimer's disease. Currently, AD is diagnosed by clinical
examination (i.e., medical history, physical, neurological, psychiatric and
neuropsychological exams, laboratory tests and Magnetic Resonance Imaging
[MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed
through histopathological identification of characteristic features, including
beta amyloid plaques, in post-mortem brain samples.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in